Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

LOS ANGELES, CA / ACCESSWIRE / June 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Is Encouraging Investors Who Have Incurred Losses With Humana Inc. To Initiate Communication

LOUISVILLE, Ky.--(BUSINESS WIRE)--University of Louisville study outlines Humana's economic and community impact on Kentucky.

University of Louisville Study Outlines Humana's Economic and Community Impact on Kentucky

Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.

Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers

LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Is Urging Investors Who Have Suffered Losses In Humana Inc. To Establish Contact

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 2, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) common stock between July 27, 2022, and January 24, 2024, inclusive (the “Class Period”). Investors suffering losses on their Humana investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humana Inc. (HUM)

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Robbins LLP  reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Humana, Inc. (NYSE: HUM) common stock between July 27, 2022 and January 24, 2024. Humana is a health insurance company that provides medical benefit plans to approximately 17 million members.

HUM Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Humana, Inc. Class Action

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Humana Inc. (NYSE: HUM) between July 27, 2022 and January 24, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 2, 2024.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Humana Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HUM

LOS ANGELES--(BUSINESS WIRE)---- $STOCKS--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Humana Inc. (HUM) Investors.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Humana Inc. (HUM) Investors

ASHEVILLE, N.C.--(BUSINESS WIRE)--CenterWell Senior Primary Care brings personalized care to Asheville seniors.

CenterWell Senior Primary Care Bringing Personalized Care to Asheville Seniors

NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Humana Inc. – HUM

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Is Urging Investors Who Have Suffered Losses In Humana Inc. To Make Contact

LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm Is Encouraging Investors Who Have Incurred Losses In Humana Inc. To Reach Out

SAN DIEGO--(BUSINESS WIRE)---- $HUM #HUM--Robbins LLP is Investigating Allegations that Humana, Inc. (HUM) Misled Investors Regarding its Business Prospects.

Humana, Inc. Investor Notice: Robbins LLP Reminds Stockholders to Seek Representation in the HUM Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) common stock between July 27, 2022, and January 24, 2024, inclusive (the “Class Period”). Humana investors have until August 2, 2024 to file a lead plaintiff motion. If you suffered a loss on your Humana investments.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Humana Inc. (HUM) Investors

LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

Investors with Losses from Humana Inc.: Schall Law Firm Encourages You to Reach Out Before the Deadline

NEW YORK , June 6, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Humana Inc. (NYSE: HUM) between July 27, 2022 and January 24, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A LEADING LAW FIRM, Encourages Humana Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUM

SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of Humana Inc. (NYSE: HUM) (“Humana” or the “Company”) common stock between July 27, 2022 and January 24, 2024, inclusive (the “Class Period”), charging the Company and certain current senior executive officers with violations of the federal securities laws.   Humana investors have until August 2, 2024 to seek appointment as lead plaintiff of the class action lawsuit.

INVESTOR ALERT:   DiCello Levitt LLP Announces the Filings of a Class Action Against Humana Inc. (NYSE: HUM)

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) common stock between July 27, 2022, and January 24, 2024, inclusive (the “Class Period”). Humana investors have until August 2, 2024 to file a lead plaintiff motion. Investors suffering losses on their Humana investments are encouraged to contact the Law Offices of Howard G. Smith to discuss t.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Humana Inc. (HUM) Investors

LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

Humana Inc. Investors with Losses: Schall Law Firm Urges You to Connect Prior to the Deadline

LOS ANGELES--(BUSINESS WIRE)--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Humana Inc. with Losses to Contact the Firm.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Humana Inc. with Losses to Contact the Firm

Humana Inc. is having short-term cost challenges and facing constrained rate increases. However, Humana's Medicare Advantage expected to benefit from demographic tailwinds and CenterWell integrated care for growth and cost mitigation. I rate Humana a buy at a price target of $396.

Humana Is Set Up For Long-Term Success

SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Humana, Inc. (NYSE: HUM) common stock between July 27, 2022 and January 24, 2024. Humana is a health insurance company that provides medical benefit plans to approximately 17 million members.

Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Humana, Inc. (HUM)

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humana Inc. (“Humana” or the “Company”) (NYSE: HUM) in the United States District Court for the District of Delaware on behalf of all persons and entities who purchased or otherwise acquired Humana common stock between July 27, 2022, and January 24, 2024, both dates inclusive (the “Class Period”). Investors have until August 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

HUMANA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humana Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2022 and January 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 2, 2024.

The Schall Law Firm is urging investors who have suffered losses in Humana Inc. to get in touch

Humana (HUM) expands its Medicare Advantage network in Alabama through a new partnership with UAB Health System, offering greater access to enhanced healthcare services.

News for Humana Stock (HUM)